Carbapenem-nonsusceptible Enterobacteriaceae in Taiwan

PloS One
Jann-Tay WangShan-Chwen Chang

Abstract

A total of 1135 carbapenem-resistant (nonsusceptible) Enterobacteriaceae (CRE) isolates were recovered between November 2010 and July 2012 (517 from 2010-2011 and 618 from 2012) from 4 hospitals in Taiwan. Carbapenemase-producing Enterobacteriaceae (CPE) comprised 5.0% (57 isolates), including 17 KPC-2 (16 Klebsiella pneumoniae and 1 Escherichia coli), 1 NDM-1 (K. oxytoca), 37 IMP-8 (26 Enterobacter cloacae, 4 Citrobacter freundii, 4 Raoultella planticola, 1 K. pneumoniae, 1 E. coli and 1 K. oxytoca), and 2 VIM-1 (1 E. cloacae, 1 E. coli). The KPC-2-positive K. pneumoniae were highly clonal even in isolates from different hospitals, and all were ST11. IMP-8 positive E. cloacae from the same hospitals showed higher similarity in PFGE pattern than those from different hospitals. A total of 518 CRE isolates (45.6%) were positive for blaESBL, while 704 (62.0%) isolates were blaAmpC-positive, 382 (33.6% overall) of which carried both blaESBL and blaAmpC. CTX-M (414, 80.0%) was the most common blaESBL, while DHA (497, 70.6%) and CMY (157, 22.3%) were the most common blaAmpC. Co-carriage of blaESBL and blaAmpC was detected in 31 (54.4%) and 15 (26.3%) of the 57 CPE, respectively. KPC-2 was the most common carbapenemase detected in K. ...Continue Reading

References

Jan 9, 1998·Infectious Disease Clinics of North America·G A Jacoby
May 31, 2002·Journal of Clinical Microbiology·F Javier Pérez-Pérez, Nancy D Hanson
Jun 7, 2005·Journal of Microbiological Methods·Alessandra CarattoliE John Threlfall
Aug 6, 2005·Journal of Clinical Microbiology·Laure DiancourtSylvain Brisse
Nov 15, 2005·The Journal of Antimicrobial Chemotherapy·Neil WoodfordMatthew J Ellington
Jun 1, 2006·The American Journal of Medicine·David L Paterson
Jul 4, 2006·American Journal of Infection Control·David L Paterson
Dec 23, 2006·The Journal of Antimicrobial Chemotherapy·Matthew J EllingtonNeil Woodford
Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Aug 2, 2007·The Annals of Pharmacotherapy·Katherine Yang, B Joseph Guglielmo
Oct 12, 2007·Future Microbiology·Laurent PoirelPatrice Nordmann
Jan 11, 2008·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·H-J MonsteinL E Nilsson
Feb 23, 2008·The Journal of Antimicrobial Chemotherapy·Yi-Fang LiuJiunn-Jong Wu
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·David M LivermoreUNKNOWN BSAC Working Parties on Resistance Surveillance
Jun 9, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M TreviñoB J Regueiro
Aug 19, 2009·The Journal of Antimicrobial Chemotherapy·David M Livermore
Aug 19, 2009·The Journal of Antimicrobial Chemotherapy·Peter M Hawkey, Annie M Jones
Jun 12, 2010·International Journal of Medical Microbiology : IJMM·Yvonne PfeiferWolfgang Witte
Aug 12, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J J YanF C Yang
Oct 6, 2010·Current Opinion in Microbiology·Karen Bush
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert A Bonomo
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Kuei-Pin ChungPo-Ren Hsueh
Apr 13, 2011·Clinical Microbiology Reviews·Thomas F O'Brien, John Stelling
May 3, 2011·The Lancet Infectious Diseases·Giuseppe CornagliaGian Maria Rossolini
Dec 3, 2011·Journal of Clinical Microbiology·Fu-Chen YangJiunn-Jong Wu
Apr 18, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R CantónUNKNOWN European Network on Carbapenemases
Jun 13, 2012·Case Reports in Medicine·Isabel TeoDavid Chadwick
Jul 18, 2012·Infection·D S OlsonD M Hofinger
Jul 18, 2012·Antimicrobial Agents and Chemotherapy·Chun-Ming LeePo-Ren Hsueh
Jul 24, 2012·Journal of Medical Microbiology·Amy Yichen HuSameer Elsayed
Jun 12, 2013·Antimicrobial Agents and Chemotherapy·Tzu-Wen HuangShan-Chwen Chang

❮ Previous
Next ❯

Citations

Feb 24, 2016·Japanese Journal of Infectious Diseases·Zheng RuiXia Xueshan
Jan 8, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P L HoV C C Cheng
Apr 7, 2016·Annals of Clinical Microbiology and Antimicrobials·Irmak Baran, Neriman Aksu
Aug 31, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mahmoud A F KhalilMohammed El-Mowafy
Mar 25, 2017·Infection·E BonnetJ Lourtet-Hascoet
Feb 28, 2018·Antimicrobial Agents and Chemotherapy·Ryota GomiYasufumi Matsumura
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·Karlijn van LoonMargreet C Vos
May 6, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Chung-Yu ChangPo-Liang Lu
May 3, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Ling-Fu HuangChin-Lu Chang
Feb 3, 2016·Antimicrobial Agents and Chemotherapy·Charbel Al-BayssariJean-Marc Rolain
Mar 30, 2016·Antimicrobial Agents and Chemotherapy·Laurent DortetThierry Naas
Apr 4, 2017·Japanese Journal of Infectious Diseases·Akiko KubomuraNobuhiko Okabe
Jun 21, 2017·Annals of Clinical Microbiology and Antimicrobials·Kaisheng LaiJiyong Yang
Dec 13, 2018·Frontiers in Microbiology·Shio-Shin JeanPo-Ren Hsueh
Nov 30, 2018·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Marie-Hélène Nicolas-ChanoineUNKNOWN “E-carb Study Group”

❮ Previous
Next ❯

Methods Mentioned

BETA
CLIS
PCR
electrophoresis

Software Mentioned

WHONET
Epi Info

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.